BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210929
DTEND;VALUE=DATE:20211002
DTSTAMP:20260515T212833
CREATED:20210521T123937Z
LAST-MODIFIED:20210521T124307Z
UID:30236-1632873600-1633132799@www.pharmajournalist.com
SUMMARY:12th Annual World Bispecific Summit
DESCRIPTION:The 12th Annual World Bispecific Summit will deliver a greater scope and penetration of innovative technical content than any other meeting. This year’s re-imagined agenda will cover unique discovery\, translational\, and manufacturing challenges faced in the bispecific field. Whatever your role and interest\, you will leave the meeting with concrete methods to employ into your strategy and pipeline to convert the promise of bispecific therapeutics into a reality for patients. \n \nDiscover who the 45+ expert speakers are\, and the topics they will examine\, including how: \n\nOSE Immunotherapeutics is pioneering their unique platform BiCKI a bispecific platform optimized for the development and manufacturing of bispecific cytokine fusion proteins\nGT Biopharma and Light Chain Bioscience are showcasing the next generation of innate cell engagers for the treatment of solid tumors\nMerus\, Pfizer\, and Innate Pharma are expanding the boundaries of biotherapeutics with tri-specific and multi-specific antibodies\nGenentech\, Pfizer\, and City of Hope are discussing approaches to reduce on-target off-tumor toxicities including dosing strategies in liquid and solid tumor indications\nXencor\, Harbour Biomed\, and Harpoon Therapeutics will discuss their unique platforms and CMC strategies for scale-up and production\nIGM Biosciences and MacroGenics will evaluate biomarker strategies for bispecific candidates during clinical development\n\nTo know more about 12th Annual World Bispecific Summit please click here.
URL:https://www.pharmajournalist.com/event/12th-annual-world-bispecific-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211009
DTSTAMP:20260515T212833
CREATED:20210301T101605Z
LAST-MODIFIED:20210301T101605Z
UID:29208-1633392000-1633737599@www.pharmajournalist.com
SUMMARY:9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference (EST TIME ZONE)
DESCRIPTION:Leveraging next gen technologies beyond conventional biomarker drug discovery \nThe emergence of the need for safety and efficacy of a drug subjected to individual patients has made companion diagnostics one of the most sought after topics in the field of In-Vitro Diagnostics. The surge of investment in companion diagnostics has brought forward issues regarding regulations and their intricacies and boosted new trends in immuno-oncology\, immuno-therapies\, data interpretation and unconventional design of clinical trials. \nThe 9th Annual MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference scheduled to be held from 5th – 8th October 2020 would address the gaps between early-stage biomarker development and the commercialization stage of biomarkers. \nThis conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. Regarding the commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to the clinical translation of biomarkers. \nEvent Website: https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/  \nRegistration link:  https://events.marketsandmarkets.com/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/9th-annual-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-est-time-zone/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211005
DTEND;VALUE=DATE:20211008
DTSTAMP:20260515T212833
CREATED:20210802T091237Z
LAST-MODIFIED:20210802T091416Z
UID:31169-1633392000-1633651199@www.pharmajournalist.com
SUMMARY:2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit
DESCRIPTION:The 2nd Annual B&T Cell-Mediated Autoimmune Disease Drug Development Summit is the only event uniting key B&T cell decision-makers to advance the therapeutic future of autoimmune diseases. \nJoin this community of 60+ pioneers to aid discovery\, development\, optimization and strategy for a new generation of treatment within this area of vastly unmet clinical need. \nThis cross-disciplinary program featuring keynote talks from 32+ clinical KOLs from large pharma\, biotech and academia\, will give you insight into the full therapeutic opportunity of drug candidates against various plasma\, B and T cell targets. \nUnite with other B & T cell researchers as we look to optimize therapeutic targeting of the bidirectional interactions between B and T cells\, B cell functions (autoantibody production\, antigen presentation\, T cell help & cytokine production) and autoreactive T cells contribution to autoimmune pathogenesis and disease progression. \nView our full event guide to see our complete speaker line-up\, latest agenda\, and workshop details. https://ter.li/0zk3pp \nKey Discussions you Can’t Afford to Miss: \n\nDelve into the exciting world of cell engineering and novel targets for rare autoimmune diseases and what they mean for the field with Abcuro\, Polyneuron\, Apitope\, NYSCF\, UTHSC & Cabaletta Bio\nDiscover the novel and promising candidates targeting B cell development factors and related cytokines with Eli Lilly & Co\, UCL\, Kyverna\, Immunic AG\, Nurix & GSK\nUncover the pathologies and targets for the B & T cell co-stimulatory pathways and novel mechanisms in disrupting collaboration with Artax Bio\, Cytocom\, Horizon\, AltruBio & Novartis\nExplore targets\, considerations and strategy for targeting autoantibody producing plasma cells\, organ specific and systemic diseases with UCB\, Provention Bio\, IM Therapeutics & Biogen\nOptimize application and patient outlook through combination strategies\, early detection and emerging biomarkers and look to next steps in your drug development with Oklahoma Medical Research Foundation\, Bristol-Myers Squibb & Eli Lilly & Co\n\nFind out more https://ter.li/0zk3pp
URL:https://www.pharmajournalist.com/event/2nd-annual-bt-cell-mediated-autoimmune-disease-drug-development-summit/
LOCATION:Digital Event | EST
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211006
DTEND;VALUE=DATE:20211008
DTSTAMP:20260515T212833
CREATED:20200520T093405Z
LAST-MODIFIED:20200731T100028Z
UID:25600-1633478400-1633651199@www.pharmajournalist.com
SUMMARY:SMi's 2nd Next Generation Pharmaceutical Cleanroom Conference
DESCRIPTION:SPONSORED BY: Elis Cleanroom and Innerspace\nCHAIRED BY: Matts Ramstorp\, CEO & Founder\, BioTekPro \nAddressing the Microbiological Aspects in Cleanroom Design & Engineering \nSMi Group are pleased to announce the 2nd Annual Next Generation Pharmaceutical Cleanroom Europe Conference. An event that focuses on cleanroom technology in the pharmaceutical industry\, the conference will serve to bridge that gap between the two areas while simultaneously providing a unique selling point. \nThis one-of-a-kind meeting will facilitate networking opportunities with key opinion leaders from all areas of pharmaceuticals\, biologicals\, and cleanroom industry experts to explore hot topics within cleanroom design and engineering\, best practices and regulation\, environmental and contamination control\, and pharmaceutical microbiology. \n \nIn 2025\, the global cleanroom technology market is expected to reach nearly $5 billion. Stringent regulatory standards for product approvals\, technological advancements in cleanrooms\, initiatives taken by private organisations to create awareness regarding cleanroom and growth of the healthcare sector globally are among the few factors expected to drive the market. \nThis event will look in-depth at the significant change that the cleanroom industry is going through. From the new operating practices that keep the product as sterile as possible\, to the developments in technology that are enabling this to happen. Whether through robotics\, automated disinfection\, or data driven environmental monitoring- this conference will highlight the developments that are fundamentally changing the industry. \nEvent Hashtag: #SMiCleanroom \nHIGHLIGHTS FOR 2021: \n\n UNDERSTAND the current regulatory landscape from both designer and regulator perspectives\n EXPLORE the innovations in technology that are shaping the next generation of cleanroom facilities\n DETERMINE the best approaches to cleanroom design and operation from global case studies\n GAIN insight into the latest developments in cleanroom protocol from leading industry experts\n\nFEATURED 2021 SPEAKERS INCLUDE: \n\nTim Sandle\, Head of Microbiology and Sterility Assurance\, Bio Products Laboratory Ltd\nConor Murray\, Principal\, Irish Cleanroom Society\nJoseph McCall\, Associate Director\, QA Technical Service\, ADMA Biologics\nBenoît  Ramond\, Head of Microbiology & Sterile Technology\, Sanofi\nWalid El Azab\, Senior Manager Technical Services\, STERIS\nDawn Tavalsky\, Senior Director Global Sterility Assurance\, Sanofi Pasteur\nPatrizia Muscas\, QA & Sterility Assurance\, Eli Lilly\nChristine Arbesser-Rastburg\, Director\, Head of Global Microbiology\, Takeda\n\nWHO SHOULD ATTEND: \nSenior Micro Manager\, QC Manager\, Quality Director\, Clean Room Design Managers\, Design\, Qualify and Testing – Clean Room (across the board)\, Head of Clean Room Technologies\, Head of Compounding Pharmacies\, Head of Clinical Drug Products\, Head of Clinical Medical Device \nADDED VALUE – 2 x Pre-Conference Workshops on…\nWorkshop A – 08.30 – 12.30: Applying ISO and EN Standards to Non-Viable and Viable EM in the context of the new Annex 1 guidance and a CCS in GMP Cleanrooms\nWorkshop Leader: Conor Murray\, Principal\, Irish Cleanroom Society  \nWorkshop B – 13.30 – 17.30: Cleanroom Garments – need\, function and use\nWorkshop Leader: Matts Ramstorp\, CEO & Founder\, BioTekPro \nView the brochure and to download visit www.cleanroomtechnology.co.uk/PJwl
URL:https://www.pharmajournalist.com/event/smis-2nd-next-generation-pharmaceutical-cleanroom-conference/
LOCATION:Copthorne Tara Hotel\, London\, United Kingdom
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211018
DTEND;VALUE=DATE:20211020
DTSTAMP:20260515T212833
CREATED:20190503T072628Z
LAST-MODIFIED:20210519T083857Z
UID:20546-1634515200-1634687999@www.pharmajournalist.com
SUMMARY:Wearable Injectors and Connected Devices Conference
DESCRIPTION:The latest innovations in digital health and on-body drug delivery for the pharmaceutical industry \nSMi’s 2nd annual Wearable Injectors and Connected Devices Conference will explore real world case studies of on-body device design and development for large volume delivery while engaging in the latest digital applications for wearable devices with industry case studies from pharma thought leaders. The conference will consider key developments in the wearable injectors field\, including the enhanced demand for on-body injectors and digitalised health as the pandemic highlights the need for self-administered at-home care\, managing sustainability in the field\, and opportunities for development in oncology. \n \nKey regulatory updates including guidance on MDR requirements and the impact of Brexit on data collection will be presented by regulatory experts for a comprehensive outlook of this exciting and ever-growing field\, and the importance of considering human factors in order to enhance the user experience will be presented by industry experts. \nThis two-day agenda offers you peer-to-peer networking with Global Device Development Managers\, Senior Connectivity Engineers\, Leaders in Device Data Generation\, Human Factors Directors and many more. \nWe look forward to welcoming you to the conference in October. \nFor more information and to register: www.wearable-injectors.co.uk/pjwl   \nBENEFITS OF ATTENDING: \n\nGain insight into developments in wearable devices in clinical trials and adapting to decentralised trials during the pandemic\nExplore design strategies for connectivity and digital health with sessions from Novartis and Bayer\nHear key regulatory updates from regulatory and notified bodies including TÜV SÜD\nDiscover advances in device design for large volume delivery via on-body injectors\nExplore and benchmark against industry developments through case studies and real-world examples in device development for on-body injectors\n\nPlus\, two interactive half-day workshops – Wednesday 20th October 2021 \nA: Cross company collaboration to develop digital therapeutic solutions using connected devices\nWorkshop Leader:\nDigby Harris\, Global Procurement Lead – Digital Therapeutics\, AstraZeneca \nB: Optimising Patient Engagement and Creating Novel Company Value through Digital Technologies\nWorkshop Leaders:\nAlex Gilbert\, Digital Medicine\, Huma \nEarly-Bird Rates \n\nBOOK BY JUNE 30TH TO SAVE £200\nBOOK BY AUGUST 31ST TO SAVE £100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiWearables\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/wearable-injectors-and-connected-devices-conference/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Limited":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211019
DTEND;VALUE=DATE:20211022
DTSTAMP:20260515T212833
CREATED:20210524T113716Z
LAST-MODIFIED:20210524T113716Z
UID:30317-1634601600-1634860799@www.pharmajournalist.com
SUMMARY:2nd Annual Dry-AMD Therapeutic Development Summit
DESCRIPTION:Returning for its 2nd year as the world’s leading industry forum\, Dry-AMD Therapeutic Development establishes meaningful clinical endpoints using the latest diagnostic imaging techniques to prove therapeutic safety and efficacy in specific patient populations. \nIn the context of unprecedented Phase III progress\, and as new investigational pharmacological agents enter the clinic\, Dry-AMD Therapeutic Development will deliver a greater breadth and depth of technical content than any other meeting in this field with 3 days and 2 tracks of dedicated content. \n \nUniting large pharma\, biotech and academic KOLs with a reimagined agenda\, this year’s meeting devotes specific content to the unique discovery\, pre-clinical\, translational\, clinical development and commercialization challenges encountered within the dry-AMD space. Ensuring that whatever your role in the field\, you will leave with tangible actions to implement into your strategy and pipeline\, to translate the promise of dry AMD therapies into a reality for patients. \nJoin the 200+ expert community\, as they unite under a common goal of accelerating the approval of next generation therapies for this progressive eye disease. \nTo know more about Dry-AMD Therapeutics Summit please click here.
URL:https://www.pharmajournalist.com/event/2nd-annual-dry-amd-therapeutic-development-summit/
LOCATION:Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211025
DTEND;VALUE=DATE:20211027
DTSTAMP:20260515T212833
CREATED:20210519T082947Z
LAST-MODIFIED:20210519T082947Z
UID:30203-1635120000-1635292799@www.pharmajournalist.com
SUMMARY:Medical Wearables for Biosensors USA Conference 2021
DESCRIPTION:Exploring therapeutic applications of connected on-body devices \nThe global wearable biosensors market is a rapidly expanding industry with increasingly growing potential for applications in healthcare and technological advances. With potential in remote patient monitoring\, diagnosis and detection of disease\, biosensors and wearable devices are gaining substantial interest due to their opportunities to offer continuous and reliable physiological information allowing for better support of patient needs. \nWith that in mind\, SMi is proud to present the Designing Biosensors for Medical Wearables Conference\, taking place on the 25th – 26th October 2021 in Boston. \n \nBENEFITS OF ATTENDING: \n\nEngage in case studies from leading experts on wearable devices for remote diagnostics and patient monitoring\nExplore how industry is using on-body biosensors for a patient centric-approach to therapeutics\nDelve into the regulatory landscape of digital health and data management with regulatory body and leading expert addresses\nUncover the evolving research into smart vaccines for COVID-19 and accelerating accessibility of new wearable technologies\n\nRegister online: www.biosensors-medical-wear.com/pjwl \nPlus\, two interactive half-day workshops – Wednesday 27th October 2021 \nA: Digital Integration within Clinical Trials \nWorkshop Leaders:\nGary McNamara\, Senior Delivery Manager\, Aparito\nDaniel Lewi\, Head of Business Development\, Aparito \nB: Energy Harvesting Systems for Body-Worn Sensors \nWorkshop Leaders:\nVeena Misra\, Distinguished Professor\, Director\, NSF Center for Advanced\nSelf-Powered Systems of Integrated Sensors and Technologies (ASSIST) \nEarly-Bird Rates \n\nBOOK BY JUNE 30TH TO SAVE $200\nBOOK BY AUGUST 31ST TO SAVE $100\n\nSOCIAL MEDIA HANDLES \nTwitter: @SMiPharm #SMiBiosensors\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/medical-wearables-for-biosensors-usa-conference-2021/
LOCATION:Sheraton Boston Hotel\, Boston\, USA (Virtual Attendance Option Available)
ORGANIZER;CN="SMi Events":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211030
DTSTAMP:20260515T212833
CREATED:20210617T150512Z
LAST-MODIFIED:20210628T073150Z
UID:30590-1635206400-1635551999@www.pharmajournalist.com
SUMMARY:4th Targeted Protein Degradation Summit
DESCRIPTION:As the most comprehensive\, industry-focused and ‘must-attend’ event in the field\, the 4th Targeted Protein Degradation Summit returns to once again explore the latest approaches\, perspectives\, and data-drive case studies that will continue to advance PROTACs\, molecular glues\, and other degrader modalities towards clinical success. \nWith 70+ world-class speakers and over 500 senior attendees from around the globe\, join the largest community of protein degradation experts for a deep dive into clinical development progress\, lessons learnt and novel strategies to develop safe\, selective and effective PROTACs\, molecular glues\, lysosomal degradation\, autophagy-mediated degraders as well as uncovering novel degrader modalities and approaches for oncology and beyond. \nKey Highlights: \n\nEvaluate the exclusive updates of ongoing clinical trials to accelerate towards the first clinically approved therapy with insights from Kymera Therapeutics\, Arvinas\, Nurix Therapeutics & Bristol Myers Squibb\nDeep dive into the methodologies of enhancing target engagement by improving target specificity\, uncovering strategies to find novel ligases and modelling of covalency to develop next generation degraders with insights from Eli Lilly\, FogPharma\, GSK & Janssen\nReview the plethora of disease indications that are being targeted by PROTACs and molecular glues including Alzheimers\, Parkinsons\, COVID-19 and AML with insights from Bristol Myers Squibb\, Progenra & Origami Therapeutics\nExplore the different approaches to penetrating the blood brain barrier\, comparing and contrasting the discovery\, development and optimization of PROTACs and molecular glues for neurodegenerative indications with insights from C4 Therapeutics & Progenra\nOutline the core mechanisms of PROTAC resistance and the approaches to overcoming this to successfully progress through preclinical and clinical studies with insights from University of Dundee\, Ranok Therapeutics & Captor Therapeutics\n\nTo know more about 4th Targeted Protein Degradation Summit please click here.
URL:https://www.pharmajournalist.com/event/4th-targeted-protein-degradation-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T212833
CREATED:20210622T141849Z
LAST-MODIFIED:20210622T141849Z
UID:30663-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:5th Complement-based Drug Development Summit
DESCRIPTION:Discover the Intricacies of Complement Pathways to Accelerate Clinical Validation & Maximize Complement-Targeting in the Pan-Disease Setting \nBuilt with Alexion\, Apellis and Annexon\, the 5th Complement-based Drug Development Summit returns for its fifth year as the definitive industry dedicated forum to maximize complement-targeting in the pan-disease setting. \nWith pivotal clinical readouts poised to be released in 2021\, this year’s summit will once again unite thought leaders in complement-based drug development. \n \nExpect to be involved in interactive discussions on: \n\nHow dysregulated complement signaling contributes to disease and how to identify novel drug targets up and downstream of C3 and C5\nPreclinical and clinical pipeline progress of diverse drug modalities\, including gene therapy approaches\, small molecule inhibitors\, antibodies\, protease inhibitors\, nucleic acids & more!\nLeveraging complement proteins in precision-based medicine as disease biomarkers and companion diagnostics\nAddressing clinical challenges of complement-targeted therapeutic sequencing\, combinations and timing of administration\nExpanding the clinical utility of complement inhibitors across rare diseases\, as well as autoimmune\, ophthalmic\, neurological and cancer settings\n\nNew for this year\, you’ll have a two-tracked agenda with more speakers\, more content and more networking opportunities than ever before! As the growth potential of novel complement-targeting therapeutics becomes apparent\, join the conversation to realize the clinical and commercial potential of complement proteins as pan-disease targets! \nTo know more about 5th Complement-based Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/5th-complement-based-drug-development-summit/
LOCATION:Virtual/Online
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T212833
CREATED:20210701T113342Z
LAST-MODIFIED:20210701T113448Z
UID:30764-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:6th Annual Neoantigen Based Therapies US Summit 2021
DESCRIPTION:Your Comprehensive End-to-End Guide to Transforming the Clinical Development of Cell & Vaccine Based Neoantigen Therapies \nThe growth and comeback of the neoantigen space has resulted in an abundance of new data\, innovative insights and valuable lessons learned on how to drive meaningful clinical responses\, all of which will be shared at the 6th Neoantigen Based Therapies US Summit. \nExploring the potential of shared neoantigens vs. personalized neoantigens and optimizing the selection and identification of the best and most immunogenic neoantigens\, the world’s leaders from the likes for BioNTech\, Gritstone\, Advaxis\, Genocea\, Treos Bio and many more will gather at the only 3-day summit focused on the exploding field of Neoantigen based Therapies. \nJoin over 100 experts to discuss what the optimal control\, clinical and combination trial designs should look like\, advances in accurate and robust validation assays\, and explore how we can manufacture effectively and at scale both shared and personalized neoantigen based therapies. \nLeave this meeting equipped with new collaborations across pharma\, biotech and academia\, and learn how to supercharge vaccine and cell immunotherapies for solid tumors and beyond. \nTo know more about 6th Annual Neoantigen Based Therapies US Summit 2021 please click here.
URL:https://www.pharmajournalist.com/event/6th-annual-neoantigen-based-therapies-us-summit-2021/
LOCATION:Digital Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T212833
CREATED:20210715T092520Z
LAST-MODIFIED:20210715T092520Z
UID:30937-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:2nd Supply Chain and Logistics for Cell Therapies Summit
DESCRIPTION:At the virtual 2nd Supply Chain and Logistics for Cell Therapies Summit\, your community will gather to network\, share exclusive insights in case-study led sessions\, and propose best practice for seamless vein-to-vein delivery at the clinical and commercial scale. \nImplement robust\, patient-centric supply chains for clinical to commercial readiness: \n\nBuild your supply strategyand manage risk and forecasting at scale by designing for growth\nMaximize your cloud-based and integrated systems and hear the latest innovations in chain of identity\n\nManage materials\, external manufacturing and facility design\n\nOptimize patient care with best practice guidelines and integrated platforms: \n\nUnderstand clinical requirementsand develop clinical strategies for seamless therapeutic delivery\nDiscuss and establish industry best practices and understand which standard practices can apply across a range of cell modalities\n\nMaintain product quality at scale for seamless delivery of autologous and allogeneic therapies: \n\nOptimize front-end processes and develop patient care organisations\nDiscuss quality control and site audits to ensure best standard of care and product quality\n\nFind out more >>> https://ter.li/mt5mh1
URL:https://www.pharmajournalist.com/event/2nd-supply-chain-and-logistics-for-cell-therapies-summit/
LOCATION:Virtual Event | Eastern Time
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211026
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T212833
CREATED:20210809T145746Z
LAST-MODIFIED:20210809T145746Z
UID:31270-1635206400-1635465599@www.pharmajournalist.com
SUMMARY:9th Advanced RWE Applications in Pharma
DESCRIPTION:Real-world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs\, drug developers can now improve their clinical trial success by identifying and retaining suitable patients through increased patient stratification. \nThese are exciting times to reunite at the 9th Advanced Real-World Evidence Applications in Pharma to discuss the efforts to advance real-world evidence’s effective generation and utilization. \nThe stage is set for a collaborative discussion platform bringing together you and other stakeholders from functions across clinical development\, RWE\, RWD\, Data Science\, Regulatory Affairs\, Medical Affairs\, HEOR\, and many more! \nJoin us in October to overcome critical challenges in generating and implementing real-world evidence to enhance clinical R&D\, support regulatory submission and decision-making\, and ultimately drive commercial success. \nClick here to download the event guide for the full agenda\n\nWhat’s New in 2021? \n2020 was an exciting year for real-world data (RWD) and real-world evidence (RWE) experts within pharma and biotech. The FDA’s high-profile acceptance of RWD as part of their review for COVID-19 treatments and vaccines for emergency use authorization was a big moment for the industry. This is now energizing RWD and RWE into R&D and clinical activities – expediting novel treatments for patients and substantially reducing drug developers’ R&D spend. \nHowever\, major questions still need answers urgently. The 9th Advanced Real-World Evidence Applications in Pharma will return in October 2021 to delve into the core industry challenges\, including: \n\nAssessing the global regulatory environment for future RWE application\nAdvanced data acquisition and analytics to enable your R&D and clinically informed decision making\nLeverage RWE in your clinical activities – from patient selection to synthetic trial arm\nHow to create a robust\, regulatory-compliant RWE framework and data package for your successful IND filing\nMaximizing your product lifecycle through a comprehensive observational data program\nEstablishing pre-competitive collaboration to deepen your understanding of diseases\, offering patients a personalized and effective treatment through RWE & RWD\n\nBook now to save up to $750
URL:https://www.pharmajournalist.com/event/9th-advanced-rwe-applications-in-pharma/
LOCATION:Virtual
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211027
DTEND;VALUE=DATE:20211029
DTSTAMP:20260515T212833
CREATED:20200618T111721Z
LAST-MODIFIED:20210729T114826Z
UID:25936-1635292800-1635465599@www.pharmajournalist.com
SUMMARY:Protein Engineering Global USA
DESCRIPTION:The series brings together a global audience and global lineup of biocatalyst and protein modifications specialists to share how to implement the new technologies. With the applications growing across pharmaceutical\, flavour & fragrance\, consumer goods\, food & beverage and agrochemical sectors\, we have created a protein and enzyme engineering platform that will allow the community to improve capabilities to industrialize sustainable enzyme products and increase product efficiency globally. \nUnderstand the challenges and requirements of the industry in their internal R&D projects to support scale-up processes\, next-generation mutant library screening\, or knowledge of machine learning and AI to optimize biocatalysts for industrial applications. \nExpand your commercial opportunities and market growth by learning what new industry sectors are seeing the benefit of enzyme engineering to synthesize unprecedented molecules of interest and engage and network with these industries to form new third-party collaborations\, allowing you to advance your market growth. \nDemonstrate advancements in your service capabilities by actively promoting the work of your technical teams through bespoke webinar opportunities\, presentations\, and interactive discussion with the industry. \nWe are delighted to be hosting Protein Engineering Global 2 miles from San Jose International Airport SJC\, and offer a special bedroom rate to the attendees of the Protein Engineering Congress: \n$199 + tax per room per night – Please call +1 408-453-6200 and quote Kisaco research/Protein Engineering. \nDownload agenda: www.proteinengineeringglobal.com/
URL:https://www.pharmajournalist.com/event/protein-engineering-congress/
LOCATION:Holiday inn San Jose- Silicon Valley\, 1350 North 1st Street\, San Jose\, CA\, 95112\, United States
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR